Efficacy and tolerability of topical 0.2% Myrtacine® and 4% vitamin PP for prevention and treatment of retinoid dermatitis in patients with mild to moderate acne

S. Veraldi, G. L. Giovene, C. Guerriero, V. Bettoli

Research output: Contribution to journalArticle

Abstract

Aim. The aim of the present study was to evaluate the efficacy and tolerability of an emulsion of 0.2% Myrtacine® and 4% vitamin PP, compared with a simple emollient cream, in the treatment of retinoid dermatitis in patients with mild-to-moderate acne. Methods. This was a prospective, multicenter, open-label, non-randomised, parallel-group study. Patients (age 12-49 years; skin phototype I-IV) with mild-to-moderate acne, who were treated with a topical retinoid for at least one month and had developed skin irritation were assigned to one of the two following treatments: 0.2% Myrtacine® and 4% vitamin PP (N.=116) or a simple emollient cream (N.=48). Both treatments were administered twice daily, 1-1.5 hours after the application of the topical retinoid. Study endpoints were improvement in signs and symptoms of retinoid dermatitis, global efficacy, reduction in acne severity, overall clinical outcome, patient satisfaction and tolerability. Results. At day 28, compared with the simple emollient cream, 0.2% Myrtacine® and 4% vitamin PP significantly decreased signs (erythema, dryness/scaling, oedema, and roughness) and symptoms (itching, stinging, burning sensation and discomfort) of retinoid dermatitis (P

Original languageEnglish
Pages (from-to)491-497
Number of pages7
JournalGiornale Italiano di Dermatologia e Venereologia
Volume147
Issue number5
Publication statusPublished - Oct 2012

Fingerprint

Niacinamide
Retinoids
Acne Vulgaris
Dermatitis
Emollients
Therapeutics
Skin
Erythema
Pruritus
Emulsions
Patient Satisfaction
Signs and Symptoms
Edema
Myrtacine

Keywords

  • Acne vulgaris
  • Dermatitis
  • Myrtaceae
  • Retinoids
  • Vitamin PP

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{fb4d5b8507d945608565bf3cdd683f55,
title = "Efficacy and tolerability of topical 0.2{\%} Myrtacine{\circledR} and 4{\%} vitamin PP for prevention and treatment of retinoid dermatitis in patients with mild to moderate acne",
abstract = "Aim. The aim of the present study was to evaluate the efficacy and tolerability of an emulsion of 0.2{\%} Myrtacine{\circledR} and 4{\%} vitamin PP, compared with a simple emollient cream, in the treatment of retinoid dermatitis in patients with mild-to-moderate acne. Methods. This was a prospective, multicenter, open-label, non-randomised, parallel-group study. Patients (age 12-49 years; skin phototype I-IV) with mild-to-moderate acne, who were treated with a topical retinoid for at least one month and had developed skin irritation were assigned to one of the two following treatments: 0.2{\%} Myrtacine{\circledR} and 4{\%} vitamin PP (N.=116) or a simple emollient cream (N.=48). Both treatments were administered twice daily, 1-1.5 hours after the application of the topical retinoid. Study endpoints were improvement in signs and symptoms of retinoid dermatitis, global efficacy, reduction in acne severity, overall clinical outcome, patient satisfaction and tolerability. Results. At day 28, compared with the simple emollient cream, 0.2{\%} Myrtacine{\circledR} and 4{\%} vitamin PP significantly decreased signs (erythema, dryness/scaling, oedema, and roughness) and symptoms (itching, stinging, burning sensation and discomfort) of retinoid dermatitis (P",
keywords = "Acne vulgaris, Dermatitis, Myrtaceae, Retinoids, Vitamin PP",
author = "S. Veraldi and Giovene, {G. L.} and C. Guerriero and V. Bettoli",
year = "2012",
month = "10",
language = "English",
volume = "147",
pages = "491--497",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "5",

}

TY - JOUR

T1 - Efficacy and tolerability of topical 0.2% Myrtacine® and 4% vitamin PP for prevention and treatment of retinoid dermatitis in patients with mild to moderate acne

AU - Veraldi, S.

AU - Giovene, G. L.

AU - Guerriero, C.

AU - Bettoli, V.

PY - 2012/10

Y1 - 2012/10

N2 - Aim. The aim of the present study was to evaluate the efficacy and tolerability of an emulsion of 0.2% Myrtacine® and 4% vitamin PP, compared with a simple emollient cream, in the treatment of retinoid dermatitis in patients with mild-to-moderate acne. Methods. This was a prospective, multicenter, open-label, non-randomised, parallel-group study. Patients (age 12-49 years; skin phototype I-IV) with mild-to-moderate acne, who were treated with a topical retinoid for at least one month and had developed skin irritation were assigned to one of the two following treatments: 0.2% Myrtacine® and 4% vitamin PP (N.=116) or a simple emollient cream (N.=48). Both treatments were administered twice daily, 1-1.5 hours after the application of the topical retinoid. Study endpoints were improvement in signs and symptoms of retinoid dermatitis, global efficacy, reduction in acne severity, overall clinical outcome, patient satisfaction and tolerability. Results. At day 28, compared with the simple emollient cream, 0.2% Myrtacine® and 4% vitamin PP significantly decreased signs (erythema, dryness/scaling, oedema, and roughness) and symptoms (itching, stinging, burning sensation and discomfort) of retinoid dermatitis (P

AB - Aim. The aim of the present study was to evaluate the efficacy and tolerability of an emulsion of 0.2% Myrtacine® and 4% vitamin PP, compared with a simple emollient cream, in the treatment of retinoid dermatitis in patients with mild-to-moderate acne. Methods. This was a prospective, multicenter, open-label, non-randomised, parallel-group study. Patients (age 12-49 years; skin phototype I-IV) with mild-to-moderate acne, who were treated with a topical retinoid for at least one month and had developed skin irritation were assigned to one of the two following treatments: 0.2% Myrtacine® and 4% vitamin PP (N.=116) or a simple emollient cream (N.=48). Both treatments were administered twice daily, 1-1.5 hours after the application of the topical retinoid. Study endpoints were improvement in signs and symptoms of retinoid dermatitis, global efficacy, reduction in acne severity, overall clinical outcome, patient satisfaction and tolerability. Results. At day 28, compared with the simple emollient cream, 0.2% Myrtacine® and 4% vitamin PP significantly decreased signs (erythema, dryness/scaling, oedema, and roughness) and symptoms (itching, stinging, burning sensation and discomfort) of retinoid dermatitis (P

KW - Acne vulgaris

KW - Dermatitis

KW - Myrtaceae

KW - Retinoids

KW - Vitamin PP

UR - http://www.scopus.com/inward/record.url?scp=84869421855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869421855&partnerID=8YFLogxK

M3 - Article

C2 - 23007255

AN - SCOPUS:84869421855

VL - 147

SP - 491

EP - 497

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 5

ER -